Sequella is a clinical-stage pharmaceutical company addressing the challenge of antibiotic-resistant bacterial diseases by focusing on first-in-class antibiotics with novel mechanisms of action. The firm's lead drug candidate SQ109 - identified from the firm's >150,000 proprietary compound library - is in Phase 2 clinical trials for treatment of both tuberculosis (TB) and gastritis (Helicobacter pylori infections), diseases complicated by growing resistance to existing drugs. In 2013, Sequella acquired a new clinical-stage (Phase 2) oxazolidinone, sutezolid, for treatment of TB and other resistant bacterial diseases. The firm also has a vigorous research program to develop novel antibiotics that target the enzyme translocase-1, an essential enzyme in all bacteria. Sequella's product portfolio addresses global health threats with significant market opportunity in disease areas of known or suspected infectious etiology: * TB (Mycobacterium tuberculosis) * Duodenal ulcers (Helicobacter pylori) * Gastric carcinomas (Helicobacter pylori) * CDI (Clostridium difficile) * Crohnâs Disease (Mycobacterium avium paratuberculosis) * Chagas Disease (Trypanosoma cruzi
